PATENT CLAIM ANALYSIS

Application Number: 15985390
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "461000"]

Abstract:
The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and/or seizure disorders with the modified release compositions is also described.

Claim (Index 31):
The method of  claim 27 , wherein the patient experiences a better side effect profile, comprising administering a first dosing regimen of at least one dosing regimen selected from a. to h. and administering a second dosing regimen of at least one dosing regimen selected from a. to i., provided the second dosing regimen ascends from the first dosing regimen and further provided the last dosing regimen is the maintenance dose and therefore will be administered for as long as the patient is in need of treatment thereof:\n a. optionally administering a dose of about 0.25 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; b. optionally administering a dose of about 0.5 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; c. optionally administering a dose of about 0.75 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; d. optionally administering a dose of about 1 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; e. optionally administering a dose of about 1.25 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; f. optionally administering a dose of about 1.5 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; g. optionally administering a dose of about 1.75 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; h. optionally administering a dose of about 2 mg of huperzine A, once every about 12 hours for at least two days and up to two weeks; i. optionally administering a dose of about 2.5 mg of huperzine A, once every about 12 hours for at least two days; wherein the huperzine A of a.-i. is administered in the pharmaceutical composition of  claim 1 .

Metadata:
- Claim Count in Document: 100.0
- Percentile: 93.0
- Lexical Diversity: 1.52174
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15898148', '15898143', '13347136', '15612665', '14748147']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6943027852594772
- 35 USC 102 Novelty (BERT): 0.5155524799651995
- Combined Prediction Score: 0.6764277547300495
- Mean Citation Score: 274.2767319999999
- Max Citation Score: 286.3879
- Similarity Product: 182.3176830544472

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test